Analysis of continuous patient data from the Czech National Register of patients with type 1 and type 2 diabetes using insulin pump therapy

Jankovec, Z.; Hahn, M.; Grunder, S.; Lacigova, S.; Cechurova, D.; Krcma, M.; Zourek, M.; Haladova, I.; Rusavy, Z.

doi:10.1016/j.diabres.2009.09.028

« Previous Next »Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 219-223, February 2010

Analysis of continuous patient data from the Czech National Register of patients with type 1 and type 2 diabetes using insulin pump therapy

Z. Jankovec
- Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
- Corresponding author. Fax: +420 377 259 676.
M. Hahn
- ArtiMed Medical Consulting GmbH, 34117 Kassel, Germany
S. Grunder
- Disetronic AG, 3401 Burgdorf, Switzerland
S. Lacigova
- Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
D. Cechurova
- Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
M. Krcma
- Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
M. Zourek
- Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
I. Haladova
- Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic
Z. Rusavy
- Medical Department I, University Hospital and Medical Faculty of Charles University, Alej svobody 80, 304 60 Plzen, Czech Republic

Received 13 May 2009; received in revised form 24 September 2009; accepted 28 September 2009. published online 26 October 2009.

Abstract

Aim

Patient data from the Czech National Register of patients treated with Continuous Subcutaneous Insulin Infusion (CSII) were evaluated to compare treatment indication, efficacy and safety with specific regard to the type of diabetes (T1 vs. T2).

Methods

Evaluation was done on complete data sets of at least 3 years from patients with either T1 diabetes (n=730, 93.1%) or T2 diabetes (n=54, 6.9%) between 1995 and 2006.

Results

HbA_1c decreased from 9.65 (±0.07) and 9.66 (±0.05) for T1 and T2 respectively to 8.24 (±0.07) for T1 and 8.52 (±0.27) for T2 after 1 year of treatment, 8.34 (±0.07) and 8.54 (±0.26) after 2 years and 8.44 (±0.07) and 8.71 (±0.25) after 3 years (adjusted mean values, ±SEM). This reduction is significant for both diabetes types. Results gathered from the safety analysis revealed almost comparable results for both patient groups (rates of adverse events of 42.5 and 34.8 for T1 and T2, per 100 patients and year).

Conclusion

Both patient groups achieved substantial reduction of HbA_1c. Safety evaluation showed that fewer patients with T2 diabetes were affected by adverse events. According to that CSII treatment for patients with T2 diabetes is similarly effective with a slightly better safety profile.

Keywords: Diabetes mellitus, Type I, Type II, CSII, Insulin pump